Legal Representation
Attorney
CHRISTINA M. LICURSI
USPTO Deadlines
Next Deadline
159 days remaining
NOA E-Mailed - SOU Required
Due Date
June 02, 2026
Extension Available
Until December 02, 2026
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 2, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 21, 2025 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Oct 21, 2025 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Oct 21, 2025 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Dec 4, 2024 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Dec 4, 2024 | OPPF | T | OPPOSITION PAPERS RECEIVED AT TTAB | Loading... |
| Nov 5, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 5, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 16, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 26, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 25, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 25, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 25, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 2, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 2, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 2, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 2, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 28, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 4, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in gene therapy; biological and pharmaceutical preparations, both comprised of therapeutic nucleic acids, namely RNA, for the treatment and prevention of genetic diseases and disorders, genomic diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders; Therapeutic preparations to modulate metabolism; pharmaceutical preparations and agents to modulate metabolism; pharmaceutical agents that modulate metabolism for scientific and research use; therapeutic pharmaceuticals for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; pharmaceutical preparations for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; therapeutic pharmaceuticals for modulating metabolism; none of the foregoing for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), osteoarthritis, or limb spasticity
Class 042
Testing, inspection, research, and development of pharmaceutical preparations for gene therapy; research and development in the field of computational biology, biotechnology and pharmaceuticals; none of the foregoing related to the treatment of pyruvate dehydrogenase complex deficiency (PDCD), osteoarthritis, or limb spasticity
Classification
International Classes
005
042